الفهرس Only 14 pages are availabe for public view
 |  | from | 280 |  |  |
| | | from | 280 | | |
Abstract
from the obtained results, it was possible to conclude the following: 1. After oral administration of Disartan capsule and LS-SNEDDS formula (A18) with dose equivalent to 30 mg Valsartan/ kg rat, the mean value of the plasma peak concentration (Cpmax) was found to be 8.26 ± 1.24 æg/ml and 14.38 ± 1.45 æg/ml respectively attained after tmax of 1.50 hr. and 0.50 hr. respectively. 2. The bioavailability of Valsartan from LS-SNEDDS relative to Disartan capsule was found to be 218.97 %. 3. The LS-SNEDDS formula (A18), showed extremely significant increase in Cpmax (1.74 fold) and AUC(0-{u221E}) (2.19 fold). 4. The desired enhancement of bioavailability of Valsartan from LS-SNEDDS was achieved via the observed shorter tmax as an indication of absorption rate and increase in the extent of drug absorption as indicated by the area under plasma concentration curve with a percentage relative bioavailability 218.97 %. Finally, LS-SNEDDS succeeded in enhancing Valsartan dissolution more significantly than liquid SNEDDS and S-SNEDDS due to the fact that LS- SNEDDS exhibited lager surface area exposed to the dissolution media. Therefore, the formulation of Valsartan as LS-SNEDDS could be a promising technique in improving its dissolution, bypassing first pass metabolism and thereby its bioavailability